PExA Strengthens Its International Patent Portfolio with Positive Patent Decisions in Europe and China
PExA AB (publ) has been granted a European patent that strengthens the company’s intellectual property protection in the field of mechanical ventilation. At the same time, the company has received positive patent decisions in both Europe and China concerning a sample preparation technology. These developments strengthen PExA’s international patent portfolio, which covers both the company’s technology and specific applications of that technology.
The recently granted European patent covers an application of PExA’s technology for analysing particles in exhaled air from patients undergoing mechanical ventilation. The patent protects a technical solution in which information obtained from these particles can be used to monitor lung conditions and help optimise ventilator treatment.
The other positive patent decisions concern a technology for preparing collected biological material for subsequent analysis. The patent authorities in Europe and China have issued positive decisions indicating that patents may be granted for the invention. The corresponding invention is already protected by a granted patent in the United States.
“It is encouraging that we have now received several positive patent decisions that further strengthen our international patent portfolio. We continuously work to develop and protect both our technology and its various applications. This is an important part of our long-term efforts to strengthen PExA’s position and create opportunities for future commercial development,” says Tomas Gustafsson, CEO of PExA.
PExA’s technology enables non-invasive sampling of biological material from the small airways of the lungs for subsequent molecular analysis. The technology is used by leading research groups, government agencies and pharmaceutical companies around the world in areas including lung cancer, asthma, COPD, pulmonary fibrosis, and occupational and environmentally related lung diseases. The company continuously works to further develop its technology platform and expand its applications in biomarker research, drug development and future diagnostics.
Patents Covered by This Press Release
A Device and Method for Non-Invasive Analysis of Particles During Medical Ventilation
- European patent: EP 2811902
- Granted on 23 September 2026.
A Sample Preparation Device
- European patent application: EP 22722803.8
- Chinese patent application: CN 202280029198.9
- Both applications have received positive decisions ahead of potential patent grants.
- Previously granted US patent: US 12,492,972.
For Further Information, Please Contact
Tomas Gustafsson, Email: info@pexa.se
This English translation has been generated automatically from the original Swedish press release. In the event of any discrepancies, the Swedish original shall prevail.
About PExA AB
PExA AB (556956-9246) has developed PExA 2.1, a patented research instrument that enables researchers to conveniently collect biological samples from the smallest airways of the lungs through a simple exhalation manoeuvre.
PExA’s technology is currently used by prominent research groups in several countries, and research conducted using the instrument has resulted in approximately 60 scientific publications, which serve as reference material for PExA’s method.
The company’s long-term objective is to market and sell diagnostic instruments for widespread diseases, such as lung cancer and COPD, for use globally in diagnosis or general screening at healthcare facilities.
By the time sales to clinics become relevant, the company intends to have developed more patient-friendly, convenient and commercially adapted products. This would enable PExA to address a significantly broader market, which currently encompasses many millions of patients worldwide.
PExA’s Class B shares are listed on Spotlight Stock Market.